Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Randomized, 2-sequence, 4-period, Fully-replicate, Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets in Healthy Adult Participants

NCT06801418 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT06801418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Randomized, 2-sequence, 4-period, Fully-replicate, Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets in Healthy Adult Participants
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 4, 2025
Completion date
June 19, 2025
Enrollment
160 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers